Incyclix Bio Employee Directory
Biotechnology ResearchNorth Carolina, United States11-50 Employees
Incyclix Bio, LLC is a biotechnology company focused on cell cycle control as a therapeutic approach to cancer. It is advancing INX-315, a potent and selective CDK2 inhibitor nearing clinical development, to address advanced and resistant cancers. The firm, founded by pioneers in CDK inhibitor discovery and development, emphasizes cyclin-dependent kinases as therapeutic targets across tumor types including ovarian, breast, and lung cancers and is based in Durham, North Carolina. Operating within biotechnology research, the company develops therapies aimed at precision oncology by targeting CDKs. A recent development is the appointment of Kseniya Simpson to its board of directors in April 2026, expanding governance with a partner from Hatteras Venture Partners.